Extended Data Fig. 8: FLVCR1 substrate-binding site mutants.
From: Structural basis of lipid head group entry to the Kennedy pathway by FLVCR1
a, FSEC analysis of wild-type or substrate-binding site mutants fused to mCerulean expressed in FLVCR1-knockout HEK293T cells. b, Western blot analysis of FLVCR1-knockout HEK293T cells expressing a vector control or wild-type or mutant FLVCR1 cDNA. GAPDH was ran on a separate gel as sample processing controls. For western blot source data, see Supplementary Fig. 1. c, Cumulative log2 fold change in cell number of HEK293T cells and FLVCR1-knockout HEK293T cells expressing a vector control or wild-type or mutant FLVCR1 cDNA. n = 3 biologically independent samples. (P-values: HEK293T WT and HEK293T FLVCR1 KO + FLVCR1 WT cDNA; p = 3x10−3, HEK293T FLVCR1 KO + FLVCR1 WT cDNA and HEK293T FLVCR1 KO + FLVCR1 Q214A cDNA; p = 9x10−1, HEK293T FLVCR1 KO + Vector and HEK293T FLVCR1 KO + FLVCR1 W125A cDNA; p = 9x10−1, HEK293T FLVCR1 KO + Vector and HEK293T FLVCR1 KO + FLVCR1 Y153A cDNA; p = 1x10−1, HEK293T FLVCR1 KO + FLVCR1 WT cDNA and HEK293T FLVCR1 KO + Vector; p = 8x10−5).
